Your session is about to expire
← Back to Search
DUET-4 Trial Summary
This trial is testing a new drug, XmAb22841, to see if it is safe and works well against cancer when given alone or with another drug, pembrolizumab.
- Advanced or Metastatic Solid Tumors
- Squamous Cell Carcinoma
- Nasopharyngeal Cancer
- Kidney Cancer
- Non-Small Cell Lung Cancer
- Breast Cancer
- Vulvar Squamous Cell Carcinoma
- Ovarian Cancer
- Cervical Cancer
- Anal Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Liver Cancer
- Bladder Cancer
- Peritoneal Carcinoma
- Endometrial Cancer
- Gastric Cancer
- Intrahepatic Cholangiocarcinoma
- Penile Cancer
- Small Cell Lung Cancer
- Prostate Cancer
DUET-4 Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
DUET-4 Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
DUET-4 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What therapeutic applications is XmAb®22841 regularly employed for?
"XmAb®22841 is a promising therapeutic for treating malignant neoplasms. It can also be used to combat unresectable melanoma, microsatellite instability high conditions, and disease progression after chemotherapy."
Is this experiment currently enrolling participants?
"Based on the clinicaltrials.gov listing, this research project is not currently looking for individuals to participate in their trial. The study was initially listed in May 2019 and last edited two days ago in late May 2022; however, there are 9205 other trials actively seeking participants as of now."
Are there any records of precedent studies involving XmAb®22841?
"Currently, 963 different trials are underway to investigate the effects of XmAb®22841. Out of these studies, 122 have progressed to Phase 3. The majority of clinical investigations for this treatment occur in Houston, Texas; however many other sites across 35772 locations have also been enlisted as trial centres."
To what degree is XmAb®22841 a risk for individuals?
"Research into the safety of XmAb®22841 is still in its infancy. Our team at Power estimates that this drug's security rating is a 1 out of 3 due to limited data supporting efficacy and safety."
To what extent is this experiment being administered to participants?
"Unfortunately, this investigation is no longer enlisting participants. It was initially advertised on May 29th 2019 and the most recent update to its listing occurred on May 27th 2022. If you are looking for other possibilities, there are 8242 clinical trials recruiting individuals with melanoma and 963 studies actively enrolling people in XmAb®22841 experiments."
How many test sites are conducting this experiment?
"This research is currently engaging with 28 different medical centres, such as UCSD Altman Clinical and Translational Research Institute Building (ACTRI) in La Jolla, UCSD Perlman Medical Offices in Los Angeles, and UC San Diego Moores Cancer Center in San Diego. Additionally, there are numerous other enrolment sites."
Share this study with friends